Rolf Hoffmann - Genmab AS Director

Director

Mr. Rolf K. Hoffmann has served as Independent Member of the Board of Directors of Genmab AS since March 28, 2017. He is Member of the Compensation Committee and the Scientific Committee of the Company. He has international management experience with expertise in creating and optimizing commercial opportunities in global markets, as well as additional expertise in PL management, governance and Corporationrationrate Integrity Agreement Management, compliance and organizational efficiency. He has over 20 years of experience in the international pharmaceutical and biotechnology industries at Eli Lilly and Amgen. He serves as Adjunct Professor Strategy and Entrepreneurship University of North Carolina Business School. He is also Member of the Board of Directors of EUSA Pharma, Inc and Trigemina, Inc., as well as Chairman of Biotest AG. Previously, he held Board Positions at SwissAmerican Chamber of Commerce, Council of Americas, International School of Zug and Luzern, University of North Carolina at Chapel Hill, International Advisory Board. since 2017.
Age 57
Tenure 7 years
Phone45 70 20 27 28
Webhttp://www.genmab.com

Genmab AS Management Efficiency

The company has return on total asset (ROA) of 8.3 % which means that it generated a profit of $8.3 on every $100 spent on assets. This is normal as compared to the sector avarege. Similarly, it shows a return on equity (ROE) of 18.38 %, meaning that it generated $18.38 on every $100 dollars invested by stockholders. Genmab AS's management efficiency ratios could be used to measure how well Genmab AS manages its routine affairs as well as how well it operates its assets and liabilities.

Similar Executives

Showing other executives

DIRECTOR Age

Ron KenediWestrock Coffee
66
Xiaoguang Wu51Talk Online Education
45
James MastrianBiglari Holdings
76
Pradeep JotwaniAcco Brands
66
Scott FordWestrock Coffee
61
Kenneth CooperBiglari Holdings
75
Hans NorkusAcco Brands
73
Scott SandellCoursera
56
Ruth PersonBiglari Holdings
74
Xing Liu51Talk Online Education
47
William JohnsonBiglari Holdings
71
Graciela MonteagudoAcco Brands
54
Edward RoffmanWestrock Coffee
64
Robert JenkinsAcco Brands
72
Gary EffrenWestrock Coffee
56
Mark RajkowskiAcco Brands
59
Margaret RandazzoWestrock Coffee
46
Ronald LombardiAcco Brands
57
James BuzzardAcco Brands
65
Thomas KroegerAcco Brands
72
Carmen ChangCoursera
73
Genmab AS, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. Genmab AS was founded in 1999 and is based in Copenhagen, Denmark. Genmab AS is traded on OTC Market in USA. Genmab AS [GMXAY] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC).

Management Performance

Genmab AS Leadership Team

Elected by the shareholders, the Genmab AS's board of directors comprises two types of representatives: Genmab AS inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genmab. The board's role is to monitor Genmab AS's management team and ensure that shareholders' interests are well served. Genmab AS's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genmab AS's outside directors are responsible for providing unbiased perspectives on the board's policies.
Birgitte Stephensen, Senior Vice President IPR and Legal
Daniel Bruno, Director, Employee Representative
Peter Kristensen, Director, Employee Representative
Nedjad Losic, Director, Employee Representative
David Eatwell, CFO and Executive VP
Paolo Paoletti, Director
Michael Bauer, Senior Vice President Clinical Development
Anthony Pagano, Senior Vice President Global Finance
Martine Vugt, Senior Vice President Strategic Initiatives
Andrew Carlsen, Senior Director, Investor Relations
Paul Parren, Sr. VP and Scientific Director
Tom Vink, Director, Employee Representative
Rick Hibbert, Director, Employee Representative
Pernille Erenbjerg, Director
Mats Pettersson, Chairman of the Board
Marisol Peron, Corporate Vice President Communications and Investor Relations
Rolf Hoffman, Independent Director
Rachel Gravesen, Senior Vice President Investor Relations and Communications
Burton Malkiel, Independent Director
Deirdre Connelly, Director
Judith Klimovsky, Executive Vice President Chief Development Officer
Tahamtan Ahmadi, Senior Vice President Oncology and Translational Medicine
Anders Pedersen, Deputy Chairman of the Board
Rolf Hoffmann, Director
Jan Winkel, President and CEO

Genmab Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Genmab AS a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
Note that the Genmab AS information on this page should be used as a complementary analysis to other Genmab AS's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.

Other Consideration for investing in Genmab Pink Sheet

If you are still planning to invest in Genmab AS check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Genmab AS's history and understand the potential risks before investing.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Content Syndication
Quickly integrate customizable finance content to your own investment portal
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Money Managers
Screen money managers from public funds and ETFs managed around the world
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets